Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting

References

• MatetzkySShenkmanBGuettaVClopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarctionCirculation2004109253171317515184279
   PubMed Web of Science ®Google Scholar
• GRAVITAS: Gauging responsiveness with a verifynow assay-impact on thrombosis and safety in patients with acute myocardial infarctionhttp://clinicaltrails.gov/ct2/show/NCT00645918
   Google Scholar
• Double randomization of montoring adjusted anti-platelet treatment versus a common anti-platelet treatment for DES Implantation, and interuption versus continuation of double antiplatelet therapy. URL http://clinicaltrials.gov/archive/NCT00827411/2009_01_21.2009
   Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering CommitteeLancet19963489038132913398918275
   PubMed Web of Science ®Google Scholar
• PatronoCAspirin as an antiplatelet drugN Engl J Med199433018128712948145785
   PubMed Web of Science ®Google Scholar
• KunapuliSPDorsamRTKimSQuintonTMPlatelet purinergic receptorsCurr Opin Pharmacol20033217518012681240
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med2009360436337519106083
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrelN Engl J Med2009360435436219106084
   PubMed Web of Science ®Google Scholar
• SuhJWKooBKZhangSYIncreased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrelCMAJ2006174121715172216754899
   PubMed Web of Science ®Google Scholar
• BlaisdellJMohrenweiserHJacksonJIdentification and functional characterization of new potentially defective alleles of human CYP2C19Pharmacogenetics200212970371112464799
   PubMedGoogle Scholar
• WiviottSDBraunwaldEMcCabeCHIntensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trialLancet200837196211353136318377975
   PubMed Web of Science ®Google Scholar
• MeiselCRootsICascorbiIBrinkmannUBrockmollerJHow to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transportClin Chem Lab Med200038986987611097342
   PubMed Web of Science ®Google Scholar
• ChristiaensLMacchiLHerpinDResistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery diseaseThromb Res20021082–311511912590946
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEInfluence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary interventionAm J Cardiol2006971384316377281
   PubMed Web of Science ®Google Scholar
• GumPAKottke-MarchantKWelshPAWhiteJTopolEJA prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular diseaseJ Am Coll Cardiol200341696196512651041
   PubMed Web of Science ®Google Scholar
• GumPAKottke-MarchantKPoggioEDProfile and prevalence of aspirin resistance in patients with cardiovascular diseaseAm J Cardiol200188323023511472699
   PubMed Web of Science ®Google Scholar
• MichelsonADPlatelet function testing in cardiovascular diseasesCirculation200411019e489e49315533872
   PubMed Web of Science ®Google Scholar
• AwtryEHLoscalzoJAspirinCirculation2000101101206121810715270
   PubMed Web of Science ®Google Scholar
• FergusonADDokainishHLakkisNAspirin and clopidogrel response variability: review of the published literatureTex Heart Inst J200835331332018941611
   PubMed Web of Science ®Google Scholar
• GremmelTSteinerSSeidingerDKoppensteinerRPanzerSKoppCWSmoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapyThromb Res2009124558859119631365
   PubMed Web of Science ®Google Scholar
• BlidenKPDichiaraJLawalLThe association of cigarette smoking with enhanced platelet inhibition by clopidogrelJ Am Coll Cardiol200852753153318687246
   PubMed Web of Science ®Google Scholar
• FavaloroEJClinical application of the PFA-100Curr Opin Hematol20029540741512172459
   PubMed Web of Science ®Google Scholar
• FontanaPNolliSReberGde MoerloosePBiological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteersJ Thromb Haemost20064481381916634751
   PubMed Web of Science ®Google Scholar
• PanicciaRAntonucciEGoriAMDifferent methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patientsJ Thromb Haemost2007591839184717723123
   PubMed Web of Science ®Google Scholar
• SmithJWSteinhublSRLincoffAMRapid platelet-function assay: an automated and quantitative cartridge-based methodCirculation19999956206259950658
   PubMed Web of Science ®Google Scholar
• GurbelPABeckerRCMannKGSteinhublSRMichelsonADPlatelet function monitoring in patients with coronary artery diseaseJ Am Coll Cardiol200750191822183417980247
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEIdentification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stentingThromb Res20051151–210110815567460
   PubMed Web of Science ®Google Scholar
• MullerIBestaFSchulzCMassbergSSchonigAGawazMPrevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placementThromb Haemost200389578378712719773
   PubMed Web of Science ®Google Scholar
• SamaraWMBlidenKPTantryUSGurbelPAThe difference between clopidogrel responsiveness and posttreatment platelet reactivityThromb Res20051151–2899415567458
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHiattBLO’ConnorCMClopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivityCirculation2003107232908291312796140
   PubMed Web of Science ®Google Scholar
• GeigerJBrichJHonig-LiedlPSpecific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrelArterioscler Thromb Vasc Biol19991982007201110446085
   PubMed Web of Science ®Google Scholar
• BuonamiciPMarcucciRMiglioriniAImpact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisJ Am Coll Cardiol200749242312231717572245
   PubMed Web of Science ®Google Scholar
• PriceMJEndemannSGollapudiRRPrognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantationEur Heart J2008298992100018263931
   PubMed Web of Science ®Google Scholar
• TantryUSBlidenKPGurbelPAOverestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulationJ Am Coll Cardiol20054691705170916256872
   PubMed Web of Science ®Google Scholar
• MichelsonADCattaneoMEikelboomJWAspirin resistance: position paper of the Working Group on Aspirin ResistanceJ Thromb Haemost2005361309131115892858
   PubMed Web of Science ®Google Scholar
• PatronoCCollerBDalenJEPlatelet-active drugs: the relationships among dose, effectiveness, and side effectsChest20011191 Suppl39S63S11157642
   PubMed Web of Science ®Google Scholar
• ChenWHLeePYNgWTseHFLauCPAspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatmentJ Am Coll Cardiol20044361122112615028378
   PubMed Web of Science ®Google Scholar
• WangJCAucoin-BarryDManuelianDIncidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASAAm J Cardiol200392121492149414675598
   PubMed Web of Science ®Google Scholar
• LeePYChenWHNgWLow-dose aspirin increases aspirin resistance in patients with coronary artery diseaseAm J Med2005118772372715989905
   PubMed Web of Science ®Google Scholar
• LevEIPatelRTMareshKJAspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistanceJ Am Coll Cardiol2006471273316386660
   PubMed Web of Science ®Google Scholar
• MacchiLChristiaensLBrabantSResistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphateThromb Res20021071–2454912413588
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPSamaraWClopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST StudyJ Am Coll Cardiol200546101827183216286166
   PubMed Web of Science ®Google Scholar
• LabartheBTherouxPAngioiMGhitescuMMatching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drugJ Am Coll Cardiol200546463864516098428
   PubMed Web of Science ®Google Scholar
• Siller-MatulaJSchrorKWojtaJHuberKThienopyridines in cardiovascular disease: focus on clopidogrel resistanceThromb Haemost200797338539317334505
   PubMed Web of Science ®Google Scholar
• HoPMMaddoxTMWangLRisk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndromeJAMA2009301993794419258584
   PubMed Web of Science ®Google Scholar
• AubertREProton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcome StudyCirculation2008(118:S):815
   Web of Science ®Google Scholar
• AngiolilloDJShoemakerSBDesaiBRandomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) studyCirculation2007115670871617261652
   PubMed Web of Science ®Google Scholar
• MullerISeyfarthMRudigerSEffect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placementHeart2001851929311119474
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHayesKMYohoJAHerzogWRTantryUSThe relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stentingJ Am Coll Cardiol20054591392139615862408
   PubMed Web of Science ®Google Scholar
• SerebruanyVLMalininAISaneDCMagnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trialEur J Pharmacol2004499331532415381054
   PubMed Web of Science ®Google Scholar
• WiviottSDAntmanEMGibsonCMEvaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)Am Heart J2006152462763516996826
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• HustedSEmanuelssonHHeptinstallSSandsetPMWickensMPetersGPharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEur Heart J20062791038104716476694
   PubMed Web of Science ®Google Scholar
• CannonCPHustedSHarringtonRASafety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trialJ Am Coll Cardiol200750191844185117980250
   PubMed Web of Science ®Google Scholar
• SchomigATicagrelor – is there need for a new player in the antiplatelet-therapy field?N Engl J Med2009361111108111119717845
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• JenningsLKEarhartABeckerRCReydermanLVeltriEHarringtonRAAbstract 3010: Thrombin receptor antagonist (TRA; SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokineticsCirculation2007116(16 MeetingAbstracts): II674–.
   Web of Science ®Google Scholar
• WuCCTengCMComparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activationEur J Pharmacol20065461–314214716890935
   PubMed Web of Science ®Google Scholar